TapewireFind a company

person · Reporting owner

Szekeres David Leslie

Disclosed activity across 3 companies

Tapewire entity
60554
SEC CIK
0001602459

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Connect Biopharma Holdings LtdCNTB · Entity 6516PresidentMarch 16, 2026March 16, 2026
GRI Bio, Inc.GRI · Entity 8336DirectorSeptember 18, 2025September 22, 2025
HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133EVP, Chief Operating OfficerJuly 13, 2023July 17, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Connect Biopharma Holdings Ltd

Report date March 16, 2026 · Filed March 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect215,739 Reported balance Holding disclosure · report date 2026-03-16 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 215,739

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2034-06-12DirectNot disclosed Reported balance Holding disclosure · report date 2026-03-16 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2034-12-26DirectNot disclosed Reported balance Holding disclosure · report date 2026-03-16 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.

Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-12-26DirectNot disclosed Reported balance Holding disclosure · report date 2026-03-16 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance Not disclosed

F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.

F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.

GRI Bio, Inc.

Report date September 18, 2025 · Filed September 22, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2035-09-18Direct39,897 Reported balance After 2025-09-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-09-18 · Grant · Acquired 39,897 · Balance 39,897

F1: Options to purchase 29,293 shares vested in full upon the date of grant and options to purchase 9,974 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Options to purchase 29,293 shares vested in full upon the date of grant and options to purchase 9,974 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.

HERON THERAPEUTICS, INC. /DE/

Report date July 13, 2023 · Filed July 17, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect33,754 Ending reported balance After 2023-07-13 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2023-07-13 · Exercise / conversion · Acquired 1,250 · Balance 31,202

F1: Restricted stock units convert into common stock on a one-for-one basis.

Row 2 · 2023-07-13 · Exercise / conversion · Acquired 4,564 · Balance 35,766

F1: Restricted stock units convert into common stock on a one-for-one basis.

Row 3 · 2023-07-13 · Tax withholding · Disposed 2,012 · Balance 33,754

F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect6,250 Reported balance After 2023-07-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-07-13 · Exercise / conversion · Disposed 1,250 · Balance 6,250

F1: Restricted stock units convert into common stock on a one-for-one basis.

F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect23,372 Reported balance After 2023-07-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-07-13 · Exercise / conversion · Disposed 4,564 · Balance 23,372

F1: Restricted stock units convert into common stock on a one-for-one basis.

F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F4: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 18, 2025 Filed Sep 22, 2025 16:06 UTC GRI Bio, Inc. GRI · Entity 8336 GrantStock Option (Right to Buy) · Derivative 39,897 $0.00 Strike: $1.93 $0.00
Disclosure

SEC source: 0001602459-25-000004 · wk-form4_1758571561.xml · derivative · entry 1

Szekeres David Leslie · CIK 0001602459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,897

Underlying: Common Stock · 39,897 shares

Expires 2035-09-18

F1 · derivative.exercise_date: Options to purchase 29,293 shares vested in full upon the date of grant and options to purchase 9,974 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.

Read SEC document
August 26, 2025 Filed Aug 27, 2025 08:25 UTC GRI Bio, Inc. GRI · Entity 8336 GrantStock Option (Right to Buy) · Derivative 10,276 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001824293-25-000143 · wk-form4_1756297514.xml · derivative · entry 1

Szekeres David Leslie · CIK 0001602459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,276

Underlying: Common Stock · 10,276 shares

Expires 2035-08-26

F1 · derivative.exercise_date: Options to purchase 6,933 shares vested in full upon the date of grant and options to purchase 3,343 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.

Read SEC document
August 13, 2025 Filed Aug 14, 2025 16:58 UTC GRI Bio, Inc. GRI · Entity 8336 GrantStock Option (Right to Buy) · Derivative 7,545 $0.00 Strike: $1.30 $0.00
Disclosure

SEC source: 0001824293-25-000116 · wk-form4_1755205093.xml · derivative · entry 1

Szekeres David Leslie · CIK 0001602459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,545

Underlying: Common Stock · 7,545 shares

Expires 2035-08-13

F1 · derivative.exercise_date: The stock option vests in 4 equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.

Read SEC document
January 23, 2025 Filed Jan 24, 2025 17:57 UTC GRI Bio, Inc. GRI · Entity 8336 GrantStock Option (Right to Buy) · Derivative 51,937 $0.69 Strike: $0.69 $35,613.20
Disclosure

SEC source: 0001824293-25-000030 · wk-form4_1737759448.xml · derivative · entry 1

Szekeres David Leslie · CIK 0001602459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,937

Underlying: Common Stock · 51,937 shares

Expires 2035-01-23

Read SEC document
August 10, 2023 Filed Aug 14, 2023 16:10 UTC GRI Bio, Inc. GRI · Entity 8336 GrantStock Option (Right to Buy) · Derivative 34,483 $2.90 Strike: $2.90 $100,000.70
Disclosure

SEC source: 0001824293-23-000156 · wk-form4_1692043784.xml · derivative · entry 1

Szekeres David Leslie · CIK 0001602459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,483

Underlying: Common Stock · 34,483 shares

Expires 2033-08-10

F1 · derivative.exercise_date: Vests as to 1/12th of the underlying shares of common stock on the date of grant, then in 11 equal quarterly installments such that the stock option is fully vested on the third annual anniversary of the date of grant.

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 4,564 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-042480 · doc4.xml · derivative · entry 5

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,372

Underlying: Common Stock · 4,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-042480 · doc4.xml · derivative · entry 4

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 2,012 $1.31 $2,635.72
Disclosure

SEC source: 0001209191-23-042480 · doc4.xml · nonDerivative · entry 3

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,754

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 4,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-042480 · doc4.xml · nonDerivative · entry 2

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,766

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 13, 2023 Filed Jul 17, 2023 21:51 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-042480 · doc4.xml · nonDerivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,202

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:28 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 4,564 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-024500 · doc4.xml · derivative · entry 5

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,936

Underlying: Common Stock · 4,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:28 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-024500 · doc4.xml · derivative · entry 4

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:28 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 2,012 $2.88 $5,794.56
Disclosure

SEC source: 0001209191-23-024500 · doc4.xml · nonDerivative · entry 3

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,952

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:28 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 4,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-024500 · doc4.xml · nonDerivative · entry 2

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,964

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 13, 2023 Filed Apr 17, 2023 21:28 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-024500 · doc4.xml · nonDerivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 18, 2023 Filed Jan 20, 2023 22:10 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantPerformance Stock Units · Derivative 49,788 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-004304 · doc4.xml · derivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,788

Underlying: Common Stock · 49,788 shares

Expires not disclosed

F1 · derivative.exercise_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested.

F1 · derivative.expiration_date: On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs are further subject to a time-based vesting schedule. The PSUs will vest in full on the first anniversary of the grant date subject to continued employment through such date. Upon vesting and settlement of the PSUs, the Reporting Person will receive a number of shares of common stock of the Issuer equal to the number of PSUs that have vested.

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:37 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 4,564 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-003564 · doc4.xml · derivative · entry 6

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 4,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:37 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-003564 · doc4.xml · derivative · entry 5

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,750

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:37 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 2,012 $3.17 $6,378.04
Disclosure

SEC source: 0001209191-23-003564 · doc4.xml · nonDerivative · entry 4

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,150

F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:37 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 4,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-003564 · doc4.xml · nonDerivative · entry 3

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,162

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 13, 2023 Filed Jan 17, 2023 22:37 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-003564 · doc4.xml · nonDerivative · entry 2

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
October 31, 2022 Filed Jan 17, 2023 22:37 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 OtherCommon Stock 1,654 $3.27 $5,412.72
Disclosure

SEC source: 0001209191-23-003564 · doc4.xml · nonDerivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,348

F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2022.

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:38 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 4,564 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-053836 · doc4.xml · derivative · entry 5

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,064

Underlying: Common Stock · 4,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:38 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-053836 · doc4.xml · derivative · entry 4

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:38 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 2,012 $3.76 $7,565.12
Disclosure

SEC source: 0001209191-22-053836 · doc4.xml · nonDerivative · entry 3

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,694

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:38 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 4,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-053836 · doc4.xml · nonDerivative · entry 2

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,706

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:38 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-053836 · doc4.xml · nonDerivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,142

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 25, 2022 Filed Jul 27, 2022 22:23 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantEmployee Stock Option (Right to Buy) · Derivative 165,961 $0.00 Strike: $3.17 $0.00
Disclosure

SEC source: 0001209191-22-043292 · doc4.xml · derivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,961

Underlying: Common Stock · 165,961 shares

Expires 2032-07-25

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 8 equal quarterly installments beginning one quarter after the date of grant (07/25/2022).

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:58 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 4,564 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-042263 · doc4.xml · derivative · entry 6

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,628

Underlying: Common Stock · 4,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:58 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-042263 · doc4.xml · derivative · entry 5

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:58 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 2,012 $3.01 $6,056.12
Disclosure

SEC source: 0001209191-22-042263 · doc4.xml · nonDerivative · entry 4

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,892

F3 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:58 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 4,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-042263 · doc4.xml · nonDerivative · entry 3

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,904

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 13, 2022 Filed Jul 15, 2022 20:58 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-042263 · doc4.xml · nonDerivative · entry 2

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 29, 2022 Filed Jul 15, 2022 20:58 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 OtherCommon Stock 1,505 $3.84 $5,782.21
Disclosure

SEC source: 0001209191-22-042263 · doc4.xml · nonDerivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,090

F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 29, 2022.

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:06 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 4,564 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-024523 · doc4.xml · derivative · entry 5

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,192

Underlying: Common Stock · 4,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:06 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-024523 · doc4.xml · derivative · entry 4

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:06 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 2,012 $6.07 $12,212.84
Disclosure

SEC source: 0001209191-22-024523 · doc4.xml · nonDerivative · entry 3

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,585

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:06 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 4,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-024523 · doc4.xml · nonDerivative · entry 2

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
April 13, 2022 Filed Apr 15, 2022 21:06 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-024523 · doc4.xml · nonDerivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,033

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:09 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 4,564 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-003364 · doc4.xml · derivative · entry 5

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,756

Underlying: Common Stock · 4,564 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant.

F4 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant.

Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:09 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-003364 · doc4.xml · derivative · entry 4

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:09 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 2,012 $8.30 $16,699.60
Disclosure

SEC source: 0001209191-22-003364 · doc4.xml · nonDerivative · entry 3

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,783

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:09 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 4,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-003364 · doc4.xml · nonDerivative · entry 2

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,795

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:09 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-003364 · doc4.xml · nonDerivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,231

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
October 13, 2021 Filed Oct 15, 2021 20:26 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantRestricted Stock Units · Derivative 55,320 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-21-060553 · doc4.xml · derivative · entry 5

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,320

Underlying: Common Stock · 55,320 shares

Expires not disclosed

F5 · derivative.exercise_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant.

F5 · derivative.expiration_date: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant.

Read SEC document
October 13, 2021 Filed Oct 15, 2021 20:26 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantEmployee Stock Option (Right to Buy) · Derivative 92,200 $0.00 Strike: $10.55 $0.00
Disclosure

SEC source: 0001209191-21-060553 · doc4.xml · derivative · entry 4

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,200

Underlying: Common Stock · 92,200 shares

Expires 2031-10-13

F4 · derivative.exercise_date: The stock option vests and becomes exercisable monthly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that the stock option will be fully vested on the four year anniversary of the date of grant.

Read SEC document
October 13, 2021 Filed Oct 15, 2021 20:26 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-060553 · doc4.xml · derivative · entry 3

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

Read SEC document
October 13, 2021 Filed Oct 15, 2021 20:26 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 433 $10.55 $4,568.15
Disclosure

SEC source: 0001209191-21-060553 · doc4.xml · nonDerivative · entry 2

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,981

F2 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

Read SEC document
October 13, 2021 Filed Oct 15, 2021 20:26 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-060553 · doc4.xml · nonDerivative · entry 1

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
July 13, 2021 Filed Jul 15, 2021 20:52 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-046791 · doc4.xml · derivative · entry 4

Szekeres David Leslie · CIK 0001602459 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,250

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).

F4 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.